BTK
Les inhibiteurs de la tyrosine kinase de Bruton (BTK) sont des composés qui ciblent spécifiquement et inhibent la BTK, une enzyme cruciale impliquée dans la signalisation du récepteur des cellules B et la régulation de l'angiogenèse. La BTK joue un rôle significatif dans la prolifération et la survie des cellules cancéreuses, en particulier dans les malignités hématologiques. En inhibant la BTK, ces composés peuvent perturber l'angiogenèse et la croissance tumorale, ce qui les rend précieux en thérapie anticancéreuse. Chez CymitQuimica, nous offrons une gamme d'inhibiteurs de la BTK de haute qualité pour soutenir vos recherches en oncologie, immunologie et angiogenèse.
172 produits trouvés pour "BTK".
Filtrer par
Pourcentage de pureté
0
100
|
0
|
50
|
90
|
95
|
100
- Tri par prix ascendant
- Tri par prix descendant
- Puretés inférieures
- Puretés supérieures
- Livraison estimée la plus rapide
ARQ 531
CAS :ARQ-531: potent oral BTK inhibitor, anti-cancer potential, IC50 of 0.85/0.39 nM for WT/C481S-BTK.Formule :C25H23ClN4O4Degré de pureté :98.68% - 99.63%Couleur et forme :SolidMasse moléculaire :478.93AS-1763
CAS :AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.Formule :C33H31FN6O3Degré de pureté :≥95%Couleur et forme :SolidMasse moléculaire :578.64IBT6A
CAS :IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.Formule :C22H22N6ODegré de pureté :99.88% - 99.88%Couleur et forme :Yellow SolidMasse moléculaire :386.45Tirabrutinib hydrochloride
CAS :Tirabrutinib hydrochloride is a potent, highly selective, irreversible oral BTK inhibitor.Cost-effective and quality-assured.Formule :C25H23ClN6O3Degré de pureté :99.27% - 99.95%Couleur et forme :White SolidMasse moléculaire :490.94MT-802
CAS :MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).Formule :C41H41N9O8Degré de pureté :95.93% - 97.60%Couleur et forme :SolidMasse moléculaire :787.82Ref: TM-T16157
1mg92,00€5mg177,00€1mL*10mM (DMSO)231,00€10mg269,00€25mg510,00€50mg692,00€100mg888,00€200mg1.251,00€Rilzabrutinib
CAS :Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).Formule :C36H40FN9O3Degré de pureté :98.28% - 99.76%Couleur et forme :White SolidMasse moléculaire :665.76Ref: TM-T12542
1mg94,00€5mg222,00€1mL*10mM (DMSO)325,00€10mg356,00€25mg620,00€50mg893,00€100mg1.251,00€500mg2.502,00€Btk inhibitor 2
CAS :Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.Formule :C24H25N5O3Degré de pureté :99.94%Couleur et forme :SolidMasse moléculaire :431.49Ref: TM-T10629
1mg34,00€2mg49,00€5mg74,00€1mL*10mM (DMSO)82,00€10mg98,00€25mg215,00€50mg356,00€100mg434,00€Acalabrutinib enantiomer
CAS :R-Acalabrutinib, a BTK inhibitor,enantiomer, is researched for cancer, autoimmune diseases, and inflammation.Formule :C26H23N7O2Degré de pureté :99.20%Couleur et forme :SolidMasse moléculaire :465.51Ref: TM-T67881
200mgÀ demander1mg80,00€5mg168,00€1mL*10mM (DMSO)178,00€10mg238,00€25mg379,00€50mg513,00€100mg707,00€Orelabrutinib
CAS :Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).Formule :C26H25N3O3Degré de pureté :97.77% - 99.54%Couleur et forme :SolidMasse moléculaire :427.49Ref: TM-T12317
1mg86,00€5mg177,00€1mL*10mM (DMSO)205,00€10mg299,00€25mg492,00€50mg682,00€100mg897,00€500mg1.791,00€DD 03-171
CAS :Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Formule :C55H62N10O8Couleur et forme :SolidMasse moléculaire :991.163DFCI-002-06
CAS :DFCI-002-06 is an orally active dual-targeted HCK/BTK PROTAC degrader, demonstrating DC₅₀ values of 1.3 nM for HCK and 4.5 nM for BTK. It retains superior antitumor activity compared to dual-targeted HCK/BTK inhibitors and induces apoptosis in cancer cells. DFCI-002-06 is applicable in studies of MYD88-mutant B-cell malignancies.Formule :C44H46N10O5Masse moléculaire :794.92BRK inhibitor P21d hydrochloride
CAS :BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.Formule :C23H23ClFN7O2Couleur et forme :SolidMasse moléculaire :483.93TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Couleur et forme :Odour SolidFDU73
FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.Couleur et forme :Odour SolidPROTAC BTK Degrader-2
CAS :PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].Formule :C47H54F2N8O13Couleur et forme :SolidMasse moléculaire :976.97PROTAC BTK Degrader-1
CAS :Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.Formule :C43H43N9O4Couleur et forme :SolidMasse moléculaire :749.86BTK-IN-5
CAS :BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,Formule :C23H32N4O5Couleur et forme :SolidMasse moléculaire :444.532LFM-A13
CAS :LFM-A13 is a highly selective BTK inhibitor; IC50 2.5 uM; targets catalytic domain; severs BCR signaling; anti-leukemic; autoimmune disease and lymphocytic leukemia research.Formule :C11H8Br2N2O2Degré de pureté :99.50%Couleur et forme :White SolidMasse moléculaire :360Ibrutinib dimer
CAS :Ibrutinib dimer is an impurity of Ibrutinib. IIbrutinib dimer is a Dimer of Ibrutinib. Ibrutinib is an irreversible Btk inhibitor (IC50: 0.5 nM).Formule :C50H48N12O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :880.99FDA-Approved Kinase Inhibitor Library
A unique collection of xnum kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.Couleur et forme :LiquidRef: TM-L1610
1mgÀ demander10μL*10mM (DMSO)À demander30μL*10mM (DMSO)À demander50μL*10mM (DMSO)À demander100μL*10mM (DMSO)À demander
